CSBR
Champions Oncology, Inc.
CSBR has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CSBR overall, supported by stronger fundamentals and stronger modeled upside.
CSBR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Strong |
CSBR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CSBR PE Valuation
CSBR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CSBR Forward outlook
There aren't enough analyst estimates for CSBR to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CSBR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.08 | -138% |
| Q2 2026 | -$0.08 | -124% |
| Q1 2026 | -$0.15 | -134% |
| Q4 2025 | $0.18 | +$0.24 |
| Q3 2025 | $0.21 | +$0.47 |
| Q2 2025 | $0.33 | +$0.87 |
| Q1 2025 | $0.44 | +$1.16 |
| Q4 2024 | -$0.06 | +$0.65 |
CSBR has swung to a loss: it lost $0.08 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CSBR on earnings quality, reporting a profit while its opponent remains loss making.
CSBR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $15.2M | +8.8% |
| Q2 2026 | $13.8M | +12% |
| Q1 2026 | $16.6M | -2.8% |
| Q4 2025 | $15M | +11% |
| Q3 2025 | $14M | -0.5% |
| Q2 2025 | $12.4M | -12% |
| Q1 2025 | $17M | +42% |
| Q4 2024 | $13.5M | +17% |
CSBR's revenue is growing: $15M last quarter, up 8.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.7% | +1.1 points |
| Q2 2026 | -3.8% | +13 points |
| Q1 2026 | -1.7% | -28 points |
| Q4 2025 | 1.2% | -4.2 points |
| Q3 2025 | -3.8% | -13 points |
| Q2 2025 | -16% | -14 points |
| Q1 2025 | 26% | +48 points |
| Q4 2024 | 5.4% | +22 points |
CSBR's operating margin was −2.7% last quarter, up 1.1 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CSBR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CSBR on profitability, with a higher operating margin.
CSBR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$547K | -199% |
| Q2 2026 | -$2.2M | -134% |
| Q1 2026 | -$1.4M | -407% |
| Q4 2025 | -$2M | -$1.6M |
| Q3 2025 | $554K | +78% |
| Q2 2025 | $6.6M | +$8.3M |
| Q1 2025 | $448K | +$1.5M |
| Q4 2024 | -$377K | -186% |
CSBR's free cash flow was −$6M over the past year, against $7M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CSBR on cash generation, producing positive trailing cash flow while its opponent burns cash.
CSBR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +65.2K shares |
| 1 year | +0.8% | +109K shares |
| 3 years | +2.9% | +391K shares |
| 5 years | +3.7% | +496K shares |
| Available history | +7.2% | +933K shares |
CSBR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $32,000 |
| Q3 2023 | $602,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CSBR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -15.0x | Net Cash |
| Q2 2026 | -22.6x | Net Cash |
| Q4 2025 | -2.3x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -3.3x | Net Cash |
| Q4 2022 | -5.2x | Net Cash |
CSBR has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CSBR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 11.5 | Oversold |
CSBR's weekly RSI is 37 (neutral) and its Stochastic is 11 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CSBR PE vs Healthcare Sector
| Metric | CSBR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CSBR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CSBR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.79 | 2.9% below |
| 20 week MA | $5.17 | 10% below |
| 50 week MA | $5.83 | 20% below |
| 100 week MA | $6.81 | 32% below |
| 200 week MA | $6.01 | 23% below |
CSBR is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CSBR on trend strength, trading above more of its moving averages.
CSBR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.71 | $11.2 | +45% |
| 2021 | $11.2 | $8.04 | -28% |
| 2022 | $8.04 | $4.48 | -44% |
| 2023 | $4.48 | $5.62 | +25% |
| 2024 | $5.62 | $8.35 | +49% |
| 2025 | $8.35 | $6.98 | -16% |
| 2026 YTD | $6.98 | $4.65 | -33% |
CSBR has finished lower in three of the last six years. It's down 33% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CSBR on returns for 2026, with the stronger performance.